Senti Bio receives Nasdaq delisting notices; amends financing, $2M NSG note sale

Senti Biosciences, Inc.

Nasdaq: bid price below $1.00 for 30 days; 180-day cure period to Feb 23, 2027.
Stockholders' equity deficit of $3.4M vs $2.5M requirement; plan due Oct 11, 2026.
Amendment authorizes $2.0M third-tranche note sale to NSG BioInnovation Fund.
NSG purchase satisfies Celadon's remaining note purchase obligation under Merger Agreement.
Contingent value right up to $60M tied to SENTI-202 milestones in proposed merger.

Featured in Daily 8-K Digest

Selected #1 for 2026-09-02. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.